Objective: This study aimed to evaluate the long-term follow-up data
and risks associated with untreated depression and antidepressant use
in pregnancy.
Method: Patients who received consultation at the Clinical
Pharmacology and Toxicology Unit at the Izmir Ataturk Research and
Training Hospital for concerns related to use of medication during
pregnancy between 2016 and 2020 were included in the study. During
the initial interviews with the patients, data were collected regarding
maternal characteristics and drug exposures. In follow-up calls after
delivery, detailed information about pregnancy and birth outcomes was
gathered.
Results: Among 2323 pregnant women who sought consultation due to
drug use during pregnancy, 17% were receiving antidepressant treatment
(398/2323). In follow-up calls, 290 women were reached. In women who
had received no therapy during pregnancy (n=240), rates of gestational
diabetes (p=0.02), pregnancy depression (p=0.01), postpartum depression
(p<0.0001), and decreased breast milk (p=0.02) were significantly higher
compared to women who continued treatment (n=50).
Conclusion: In pregnant individuals with an ongoing antidepressant
use, the benefits and risks of antidepressant continuation should be
weighed carefully.
Keywords: Antidepressant, depression, newborn, pregnancy